Charles Schwab Investment Management Inc. Purchases 8,918 Shares of XBiotech Inc. $XBIT

Charles Schwab Investment Management Inc. boosted its position in XBiotech Inc. (NASDAQ:XBIT) by 15.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,355 shares of the biopharmaceutical company’s stock after buying an additional 8,918 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of XBiotech worth $218,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC increased its holdings in shares of XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 3,661 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of XBiotech by 42.0% during the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 5,887 shares during the last quarter. Northern Trust Corp increased its holdings in shares of XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock worth $835,000 after acquiring an additional 27,909 shares during the last quarter. Finally, Deutsche Bank AG acquired a new position in shares of XBiotech during the 4th quarter worth approximately $120,000. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Price Performance

XBIT opened at $2.98 on Friday. The business has a fifty day simple moving average of $3.04 and a 200 day simple moving average of $3.02. The company has a market capitalization of $90.86 million, a PE ratio of -3.24 and a beta of 0.85. XBiotech Inc. has a 1 year low of $2.50 and a 1 year high of $8.32.

XBiotech (NASDAQ:XBIT) last released its earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.